Quadrant Capital Group LLC Tricida, Inc. Transaction History

Quadrant Capital Group LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	BUY	$8.51 - $13.6 $893 - $1,428	105 Added 25.18%	522 $5,000
Q2 2022 Aug 09, 2022	BUY	$7.31 - $11.85 $3,048 - $4,941	417 New	417 $4,000
Q2 2021 Aug 09, 2021	SELL	$3.95 - $5.41 $513 - $703	-130 Closed	0 $0
Q1 2021 May 12, 2021	BUY	$4.52 - $7.8 $587 - $1,014	130 New	130 $1,000

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Quadrant Capital Group LLC, based on Form 13F filings with the SEC.

Stay updated on Quadrant Capital Group LLC with notifications on news.